Genentech Inc. South San Francisco, said its...

Genentech Inc. South San Francisco, said its foreign licensee, Boehringer Ingelheim International GmbH, has received approval to market T-PA in France for the treatment of heart patients. T-PA is a human protein that dissolves blood clots that cause heart attacks.